Related Experiment Video
Updated: Jun 23, 2026
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
Published on: May 9, 2018
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I
Nobumichi Tanaka1, Kiyohide Fujimoto, Yoshihiko Hirao
1Department of Urology, Nara Medical University, Kashihara, Japan. sendo@naramed-u.ac.jp
Objectives:
To evaluate the chronologic changes in the International Prostate Symptom Score (IPSS), uroflowmetric parameters, and prostate volume (PV) in patients who received low-dose-rate brachytherapy.
Methods:
Between July 2004 and December 2006, 110 patients received low-dose-rate brachytherapy. Of the 110 patients, 82 were treated with seed implantation alone and 28 with combined external beam radiotherapy. The IPSS, uroflowmetric parameters, and PV were evaluated before seed implantation and at 1, 3, 6, and 12 months after seed implantation.
Results:
The mean IPSS showed a significant increase at 1 and 6 months after seed implantation and had returned to baseline 12 months later. The maximal flow rate, voided volume, and postvoid residual urine volume showed transient deterioration at 1 and 6 months after seed implantation and had returned to the baseline 12 months later. The mean PV compared with the baseline PV showed a significant 3.8-cm(3) decrease (11.2%) at 12 months after implantation. The patients who did not receive neoadjuvant hormonal therapy had a 5.9-cm(3) decrease in PV (20.2%) 12 months later. In contrast, those who received neoadjuvant hormonal therapy had no change in PV after seed implantation.
Conclusions:
This is the first report to evaluate the chronologic changes in subjective parameters (IPSS) and objective parameters (uroflowmetry) and PV, concurrently. The changes in subjective parameters correlated with the changes in objective parameters during the first 12 months after seed implantation. The change in the PV was different after seed implantation in patients with or without neoadjuvant hormonal therapy.
